ABSTRACT
INTRODUCTION
Growing evidence has led to uncertainty about the role of dairy fat in health. Although the major saturated fat palmitic acid increases LDL cholesterol, it also lowers triglyceriderich lipoproteins, increases HDL cholesterol, and has uncertain effects on apolipoprotein C-III (1, 2) . Dairy fat also includes medium-chain triglycerides that have been linked to improved 2 DE OLIVEIRA OTTO ET AL.
FIGURE 1
Structure of fatty acids found in dairy fat. Pentadecanoic (15:0) and heptadecanoic (17:0) acids are long-chain SFAs (no carboncarbon double bonds) containing 15 and 17 carbon atoms respectively. trans-Palmitoleic acid (trans-16:1n-7) is a long-chain MUFA (one carboncarbon double bond) containing 16 carbon atoms and 1 double bond in the trans configuration. Because mammals cannot synthesize odd-chain or transfatty acids in appreciable amounts, circulating concentrations of these fatty acids represent exogenous sources. Among different foods, the strongest correlations are seen for dairy consumption (r ∼ 0.7 based on 24-h recalls or 7-d food records). Biological properties, effects on physiologic risk factors, and relevant molecular pathways of these fatty acids remain mostly unknown.
health (1) , unsaturated fats, and fat-soluble nutrients, including vitamin D, potassium, phosphorus, and calcium (3) . Prospective observational studies have generally shown neutral or beneficial associations between self-reported consumption of some dietary sources of dairy fat, such as cheese or butter, with the risk of cardiovascular disease (CVD) and diabetes (4) (5) (6) (7) (8) . Self-reported consumption may be limited by errors or reporting bias. In addition, beyond common sources such as cheese or butter, dairy fat may be variably consumed in small amounts across a large range of foods in the food supply, including small amounts of unrecognized or underrecognized milk, cream, cheese, or butter in baked goods, pasta and cream sauces, pizza, fried foods, coffee drinks, and numerous other foods. Thus, self-reported estimates may miss substantial sources of dairy fat in the diet.
These limitations can be reduced by the use of circulating fatty acid measurements, which provide objective measures of fatty acid concentrations in the blood. Circulating pentadecanoic (15:0), heptadecanoic (17:0) and trans-palmitoleic (trans-16:1n-7) acids each correlate with self-reported dairy consumption (r ∼ 0.7 based on 24-h recalls or 7-d food records) (9) (10) (11) and are significantly increased in response to dairy or wholefat dairy consumption in controlled trials (12, 13) . These fatty acids are also correlated with each other, even though odd-chain saturated fats (pentadecanoic, heptadecanoic) and the naturally occurring ruminant trans fat (trans-palmitoleic acid) have very different metabolism and chemical structures (Figure 1 ). Yet, only a handful of studies have evaluated the relation of these biomarkers with specific health outcomes, such as diabetes and CVD, with mixed findings (7, (14) (15) (16) (17) (18) (19) (20) . No previous studies, to our knowledge, have evaluated all-cause mortality. This is particularly relevant given that higher saturated-fat consumption, in comparison with carbohydrates, increases blood LDL but also increases HDL and decreases triglycerides (21) , raising questions with regard to the net effect on total and causespecific mortality endpoints. In addition, previous studies have evaluated only a single fatty acid measure at baseline, which may not account for potential changes over time. In comparison, serial fatty acid measurements allow estimation of long-term exposure (22) , which may be most relevant to chronic disease outcomes. To elucidate potential long-term health effects of dairy fat, we assessed the prospective associations of plasma phospholipid concentrations of pentadecanoic, heptadecanoic, and trans-palmitoleic acids, measured serially at baseline, 6 y, and 13 y, with total and cause-specific mortality and incident CVD in the Cardiovascular Health Study (CHS).
METHODS

Design and population
The CHS is a population-based, prospective cohort study designed to investigate risk factors for coronary heart disease (CHD) and stroke (primary endpoints) in US older adults (≥65y) (23) . In 1989-1990, 5201 noninstitutionalized older adults from 4 US communities (Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Allegheny County, Pennsylvania) were randomly recruited from Medicare eligibility lists. From 1992 to 1993, 687 additional black participants were recruited during a supplementary recruitment from the field centers in North Carolina, California, and Pennsylvania using similar methods. Among all eligible adults contacted, 57% were enrolled into the study who were slightly healthier than those who declined to participate. Participants attended annual in-clinic evaluations where repeated phenotypes related to health were obtained through physical examination, diagnostic testing, blood sampling, and questionnaires on health status, medical history, and lifestyle. Information on health status and hospitalizations was also collected via follow-up telephone calls every 6 mo through 2000 and biannually thereafter. All procedures were carried out by trained personnel using standardized procedures. Study protocols were approved by local institutional review boards, and all participants gave written informed consent. Plasma phospholipid fatty acid concentrations were measured in CHS participants with available stored blood samples at the 1992-1993 (n = 3941; 71% of living cohort participants at this visit), 1998-1999 (n = 1400; 48% of living cohort participants), and 2005-2006 (n = 935; 89% of living cohort participants) study visits. In this analysis, we included the 2907 CHS participants who had plasma phospholipid fatty acid measures available in 1992-1993 (the baseline for this analysis) and were free of CVD (Supplemental Figure 1) .
Study measures
Fatty acid measurements
Blood was drawn after 12 h of fasting, stored at −70°C, and shipped on dry ice for long-term storage at −80°C. As previously described in detail (24, 25) , total lipids were extracted from plasma at the Fred Hutchinson Cancer Research Center Biomarker Laboratory using the methods of Folch et al. (26) , and phospholipids were separated from neutral lipids by using one-dimensional, thin-layer chromatography. Fatty acid methyl esters were prepared by direct transesterification by using the methods of Lepage and Roy (27) and separated by using gas chromatography. Quantitative measurements of 45 fatty acids were expressed as a weight percentage of total phospholipid fatty acids measured. Interassay CVs for dairy fatty acids were 3 4.7% (pentadecanoic), 1.2% (heptadecanoic), and 2.9% (transpalmitoleic).
Covariates
The CHS assessed repeated measures of major risk factors during study clinic examinations in 1992-1993, 1998-1999, and 2005-2006 , including demographic characteristics, medical history, prescription medications, anthropometric measures, blood pressure, and laboratory values, each obtained using standardized equipment and procedures. Leisure activity was assessed by using a modified Minnesota Leisure-Time Activities questionnaire that evaluated the frequency and duration of 15 activities (15) . Diet was assessed in [1989] [1990] with the use of a validated 99-item food-frequency questionnaire adapted from the National Cancer Institute (28) , and again in 1995-1996 with the use of a validated Willett food-frequency questionnaire (29) . Foodfrequency questionnaires assessed usual intake of various foods including whole-fat dairy products, such as whole milk, cheese, and butter, as well as low-fat dairy milk (1% fat and skim milk), cottage cheese, and yogurt. We used the average of reported intakes from the 2 food-frequency questionnaires to reduce within-person variation and to obtain estimates of long-term intakes of dietary risk factors that could be confounders in the relations of interest such as red meat, fruit, and vegetables.
Ascertainment of endpoints
Participants were followed-up through in-clinic examinations or telephone contacts every 6 mo through 2000 and through biannual telephone contacts thereafter. Vital status follow-up was 100% complete; <1% of all person-time was otherwise missing and censored early. All-cause and cause-specific mortality, as well as all suspected incident (fatal or nonfatal) CHD and stroke events, were assessed and adjudicated by a centralized events committee using available data from interviews, next of kin, death certificates, and medical records including diagnostic tests and consultations. Algorithms and methods for follow-up, confirmation, and classification of deaths, CHD, and stroke have been described (20) (21) (22) . Total incident CVD comprised myocardial infarction, CHD death, cardiac arrest, other atherosclerotic death, stroke, stroke death, or other CVD death. CHD events comprised myocardial infarction or CHD death. CVD mortality included deaths due to CHD, stroke, other atherosclerotic disease, and other CVD. Non-CVD mortality outcomes included deaths due to cancer, pulmonary diseases, infection, dementia, fractures/trauma, and other causes. The primary outcomes for this analysis were total mortality, cause-specific mortality (CVD, CHD, stroke, and non-CVD mortality), incident CVD, and CVD subtypes (CHD and stroke). In exploratory analysis, we evaluated individual associations with subcategories of non-CVD mortality.
Statistical analysis
We estimated HRs for each outcome with the use of Cox proportional hazards [PROC PHREG procedure for timedependent variables in SAS (30) ] with time-at-risk until death, first event (for incident CVD), or last date of adjudicated followup. We found no evidence of violation of the proportional hazards assumption on the basis of Schoenfeld residuals and of Wald tests of time-dependent interactions included in Cox models (i.e., interactions of the predictors and a function of follow-up time). To obtain estimates of long-term exposure with reduced measurement error due to within-person variation over time (22) For any missing values of fatty acids, previous values were carried forward. Associations with each circulating fatty acid were evaluated in quintiles as indicator variables and continuously by using the interquintile median range (defined as the difference between the median of the first and fifth quintiles). Potential nonlinear responses were also explored by using restricted cubic splines.
Multivariable analyses were adjusted for age, sex, race, education, and enrollment site at baseline, as well as time-varying risk factors such as smoking status, prevalent diabetes, prevalent hypertension, prevalent atrial fibrillation, physical activity, BMI, waist circumference, and alcohol intake. Final covariates were selected on the basis of biological interest, well-established relations with mortality in older adults, or associations with exposures (25) . We imputed missing covariate data (<2% for most lifestyle factors; 8-12% for dietary factors) with the use of single imputation (SAS proc MI) by using multiple demographic and risk variables; results were similar when missing values were excluded. All P values were 2-sided, with P < 0.05 indicating significance. Analyses were performed with the use of Stata, release 12.0 (StataCorp), and SAS, version 9.4 (SAS Institute).
RESULTS
At baseline, mean ± SD age was 74.8 ± 5.2 y, 64% of participants were female, and 87% were white. In unadjusted crosssectional analysis, quintiles of pentadecanoic, heptadecanoic, and trans-palmitoleic acids had comparable patterns of associations with demographic, clinical, and dietary risk factors. For example, compared with the lowest quintile, participants in the highest quintile of each fatty acid were more likely to be white, have some college education, have diabetes or treated hypertension, and consume less alcohol ( Table 1) . Mean fatty acid values slightly increased over time (Supplemental Figure 2 ). Partial Spearman correlations across different fatty acids at any time point ranged from 0.47 to 0.66, consistent with their sharing a common source ( Table 2) . Repeated within-individual measures of each fatty acid over 3 time points ranged from 0.83 to 0.96.
Total mortality
During 22 y (37,498 person-years) of follow-up, 2428 deaths occurred (6.4 deaths per 100 person-years). In multivariate models adjusting for sociodemographic, lifestyle, cardiovascular, and dietary factors, there was no significant association 4 DE OLIVEIRA OTTO ET AL. 
Intake of vegetables, servings/d
2.9 ± 1.4
2.9 ± 1.5
Intake of red meat, servings/d 0.9 ± 0.6
Total circulating trans-fatty acids, % fatty acids between quintiles of plasma phospholipid pentadecanoic, heptadecanoic, and trans-palmitoleic acids and total mortality (Ptrend across quintiles = 0.19, 0.25, and 0.14, respectively; Table 1 ). When we explored potential nonlinear associations with the use of cubic spline analysis (31), we found little evidence of nonlinear associations between circulating fatty acids pentadecanoic, heptadecanoic, or trans-palmitoleic acids and risk of all-cause death (P-nonlinearity > 0.05 each).
Cardiovascular mortality
When we evaluated cause-specific mortality, plasma phospholipid heptadecanoic acid was associated with lower CVD mortality, with ∼25% lower risk in quintiles 2-5, compared with the lowest quintile (Figure 2 , Supplemental Table 1 ). This inverse association remained significant when evaluated continuously (HR per interquintile range: 0.79; 95% CI: 0.65, 0.97), with little evidence for nonlinearity in spline analyses (P-nonlinearity = 0.22). Assessing CHD and stroke mortality separately, the inverse association appeared strongest for stroke deaths [HR (95% CI): 0.58 (0.35, 0.97) for extreme quintiles and 0.61 (0.40, 0.94) per interquintile range; Supplemental Table 2 ], with evidence of inverse linear trend across quintiles (Ptrend = 0.04; Supplemental Table 2 ). Pentadecanoic and transpalmitoleic acids had no significant associations with total CVD, CHD, or stroke mortality; as well as little evidence of nonlinear associations (P-nonlinearity > 0.05 each; Supplemental Tables 1 and 2 ). All of these relations appeared to be similar in men and women.
Noncardiovascular mortality
In multivariate-adjusted analyses, heptadecanoic acid, but not pentadecanoic or trans-palmitoleic acids, was associated with a higher risk of non-CVD mortality, with an ∼25% higher risk in the highest quintile compared with the lowest (HR: 1.27; 95% CI: 1.07, 1.52; P-trend = 0.01; Figure 2 , Supplemental Table 1 ). Assessed continuously, a 17% higher risk was seen across the interquintile range of heptadecanoic acid (HR: 1.17; 95% CI: 1.01, 1.35), with little evidence for nonlinearity (P-nonlinearity = 0.83). When we explored subcategories of non-CVD mortality, including deaths due to cancer (468 deaths), respiratory diseases (132 deaths), infection (192 deaths), dementia (462 deaths), fractures/trauma (129 deaths), and other causes (212 deaths), no significant associations were evident for any of these subtypes (Supplemental Table 3 , Supplemental Figure 3 ).
Incident total CVD
When we assessed total incident CVD including fatal and nonfatal events (n = 1301 events), we found no significant associations of circulating phospholipid pentadecanoic, heptadecanoic, or trans-palmitoleic acids with risk (Figure 3 , Supplemental Table 4 ), except that pentadecanoic acid was associated with a trend toward higher CHD incidence across quintiles (P-trend = 0.02), with evidence of nonlinearity in cubic spline analyses (P-nonlinearity < 0.01; Supplemental Figure 4) . None of the fatty acids were significantly associated with incident ischemic or hemorrhagic stroke evaluated separately (data not shown). Nonlinear associations with incident CVD were not evident for heptadecanoic or trans-palmitoleic acids (P-nonlinearity >0.05 each). Directions and magnitudes of these findings were generally similar in men and women.
DISCUSSION
In this prospective study in older US adults, we evaluated, for the first time to our knowledge, the associations of serial measures of circulating fatty acid biomarkers of dairy fat with total mortality, cause-specific mortality, and incident CVD. In multivariable analyses, none of these fatty acids were associated with total mortality. Higher plasma phospholipid heptadecanoic 6 DE OLIVEIRA OTTO ET AL.
FIGURE 2
Risk of total and cause-specific mortality according to quintiles of circulating dairy fatty acids in 2907 older US adults. Values are HRs (95% CIs) estimated by using multivariable Cox proportional hazards models including age (years), sex, race (white or nonwhite), education (less than high school, high school, some college degree or more), enrollment site (4 sites), time-varying smoking status (never, current, or former), alcohol (servings per week), leisure-time physical activity (kilocalories per week), BMI (kg/m 2 ), drug-treated hypertension (yes or no), self-reported general health (excellent, very good, good, or fair/poor), circulating total trans-fatty acids (%), and self-reported consumption of dairy foods, dietary fiber, fruit, vegetables, and red meat. CVD, cardiovascular disease; Q, quintile.
acid was associated with lower CVD mortality, especially stroke mortality, with a 42% lower risk of the latter when comparing participants in extreme quintiles. In contrast, pentadecanoic acid, but not heptadecanoic or trans-palmitoleic acids, was associated with a trend toward a higher risk of total CVD and CHD across quintiles, although this association should be interpreted cautiously because it was not significant within any of the individual quintiles or in analysis using continuous measures. In exploratory analysis, the association between circulating phospholipid pentadecanoic acid and CVD risk, especially CHD risk, appeared to be nonlinear with a U-shaped curve. Finally, heptadecanoic acid was associated with a higher risk of non-CVD mortality, without a clear concentration of risk for any subtype of non-CVD death. These findings expand on previous studies by using repeated circulating fatty acid measures to estimate longterm exposure and examining associations with total and causespecific mortality and CVD outcomes in a large, prospective cohort of older adults.
Although for decades dairy fat consumption has been hypothesized to be a risk factor for CVD, as well as potentially diabetes, weight gain, and cancer (32) (33) (34) , little empirical evidence for these effects existed from studies of clinical events. In current years, a growing number of prospective studies have shown generally neutral or protective associations between self-reported dairy foods and dairy fat consumption with the risk of CVD, diabetes, weight gain, and cancers, raising questions about this conventional wisdom (32, (35) (36) (37) (38) (39) (40) . Dairy fats comprise predominantly SFAs of varying carbon chain lengths with divergent effects on various blood lipids, glucose-insulin homeostasis, and insulin resistance (1, 41) , which may partially explain neutral associations. In addition, emerging evidence from randomized controlled trials suggests the differential effects of dairy foods on plasma lipids might be influenced by the presence of milk-fat globule membrane, a tri-layered membrane rich in bioactive phospholipids and proteins enclosing the milk fat (42) (43) (44) . Consistent with these divergent and complex physiologic effects, our results suggest that overall dairy fat consumption later in life does not significantly influence total mortality but may have associations with specific outcomes.
The lower risk of stroke mortality with higher heptadecanoic acid concentration is consistent with previous large studies evaluating associations between self-reported saturated fat consumption and stroke risk (45) (46) (47) (48) (49) . For example, recent findings from the Prospective Urban Rural Epidemiology (PURE) Study, including >130,000 diverse participants from 18 countries, showed an RR for total stroke of 0.79 (95% CI: 0.64, 0.98) across quintiles of saturated fat intake (48) . Observational studies suggest potential antihypertensive and antithrombotic effects of nutrients in dairy foods, including calcium, vitamin D, phosphorus, and potassium, which could lower stroke risk (50) (51) (52) (53) (54) (55) . Dairy-specific SFAs also increase HDL cholesterol (1), which could reduce cerebral vascular fragility (45, 56) , particular in populations with a relatively low consumption of saturated fat. This potential mechanism is supported by 3 Japanese cohorts in middle-aged adults that reported inverse associations between very low intakes of saturated fat and the risk of hemorrhagic stroke or stroke mortality (45) (46) (47) , with stronger effects observed in stroke-related lesions in perforating artery regions (45) . The FIGURE 3 Risk of CVD incidence according to quintiles of circulating dairy fatty acids in 2907 older US adults. Values are HRs (95% CIs) estimated by using multivariable Cox proportional hazards model including age (years), sex, race (white or nonwhite), education (less than high school, high school, some college degree or more), enrollment site (4 sites), time-varying smoking status (never, current, or former), alcohol (servings per week), leisure-time physical activity (kilocalories per week), BMI (kg/m 2 ), drug-treated hypertension (yes or no), self-reported general health (excellent, very good, good, or fair/poor), circulating total trans-fatty acids (%), and self-reported consumption of dairy foods, dietary fiber, fruit, vegetables, and red meat. CHD, coronary heart disease; CVD, cardiovascular disease; Q, quintile.
lack of significant associations with pentadecanoic acid may be partially due to potential differences in biological processes related to fatty acid absorption (57, 58) or to differing effects of heptadecanoic and pentadecanoic acid on cardiometabolic pathways (59) . In the present analysis, we observed stronger associations of heptadecanoic acid with fatal stroke, compared with nonfatal and total stroke, suggesting a possible relation with more severe stroke cases in older adults.
Among 3 previous studies investigating associations of circulating pentadecanoic, heptadecanoic, or trans-palmitoleic acids with stroke, 2 reported no significant associations, whereas one nested case-control study reported inverse associations of plasma phospholipid heptadecanoic, but not pentadecanoic, acid with stroke, with stronger associations in women than in men (60) . These previous studies evaluated predominantly middleaged US or Swedish adults and were limited to a single baseline fatty acid measure. Our findings extend these previous results by using repeated measures to estimate long-term exposure in older adults, in whom the risk of stroke is greatest, and by evaluating total and fatal stroke separately. Our data highlight the need for additional studies to elucidate potential mechanisms underlying the observed relation between dairy fatty acids and stroke risk.
Overall, our findings do not support harmful associations of dairy fat consumption for incident CVD events later in life. These results are supported by cohorts evaluating self-reported wholefat dairy consumption. In a meta-analysis including ∼76,000 middle-aged participants with ∼5500 CVD events, pooled RRs (95% CIs) per 200 g whole-fat dairy intake/d were 0.93 (0.84, 1.03) for total CVD and 0.99 (0.93, 1.05) for CHD (61) . In a meta-analysis of 4 cohorts that used biomarkers and included a total ∼5000 middle-aged adults with ∼2200 CHD events, pooled extreme-tertile RRs (95% CIs) for CHD were 0.94 (0.67, 1.32) for pentadecanoic acid, 0.77 (0.63, 0.93) for heptadecanoic acid, and 0.96 (0.86, 1.08) for trans-palmitoleic acid (7). In light of the previous evidence, the potential higher risk of CHD we observed across quintiles of pentadecanoic acid should be interpreted cautiously, particularly because associations were not seen within individual quintiles or when evaluated continuously. Taken together, the findings from our investigation and previous studies suggest no major effects of dairy fatty acids on CVD risk.
The observed positive association of heptadecanoic acid with a higher risk of non-CVD mortality warrants further investigation. Evidence for effects of dairy fat on cancer mortality, dementia, or inflammatory conditions has been mixed (41, (62) (63) (64) (65) . In our analysis, higher mortality risk did not appear to be concentrated in any one cause of non-CVD death. Because of the absence of an a priori hypothesis related to non-CVD outcomes, these findings should be interpreted cautiously. Additional studies are needed to further evaluate potential effects of heptadecanoic acid on non-CVD mortality outcomes.
Our study has important strengths. The use of serial biomarker measurements provided objective measures of long-term exposure free from memory recall, while reducing measurement error due to changes in exposure over time. The prospective cohort design minimized recall and selection bias, established temporality, and minimized the possibility of reverse causation. Adjustment for major risk factors at the time of each fatty acid measurement 8 DE OLIVEIRA OTTO ET AL. reduced the potential for confounding. The broad, communitybased recruitment strategy increased generalizability.
Potential limitations deserve consideration. Although the use of biomarkers has several advantages, circulating fatty acid measures may reflect both dietary intake and metabolism and do not distinguish between different food sources of dairy fat. In addition, 3 serial fatty acid measures included in our analysis may not fully capture potential changes in dairy fat intake over 22 y of follow up. Evidence from animal studies suggests that pentadecanoic acid and heptadecanoic acid may be endogenously produced by elongation of propionic acid (3:0) and heptanoic acid (7:0) (58, 66) , or by α-oxidation of stearic acid (18:0) (67) . Also, we cannot exclude the possibility of residual confounding, particularly by other components in dairy foods, such protein, lactose, or minerals, or by unmeasured or imprecisely measured confounders. Although events were centrally adjudicated, some deaths may have been misclassified, which would probably be random with respect to fatty acid measures and may lead to potential attenuation of true relations. CHS data were not initially generated to address the aims of the present analysis. The CHS included older men and women, and results may not be generalizable to younger populations.
In summary, our prospective investigation of older adults suggests no major associations between long-term exposure to circulating dairy fatty acids and total mortality, with a potential protective association of heptadecanoic acid with CVD and stroke mortality and a potential higher risk for heptadecanoic acid and non-CVD death.
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Figure S4a
Supplemental Figure S4a and S4b: Adjusted hazard ratio of CVD (S3a) and CHD (S3b) risk according to concentrations of plasma phospholipid 15:0, evaluated using restricted cubic splines. Multivariable model included age at baseline, sex, race, education, enrollment site, smoking status, alcohol, leisure-time physical activity, body mass index, and self-reported general health. The analysis excluded participants below the 1 st percentile and above the 99 th percentile. The solid and dashed lines represent the central risk estimates and 95% confidence intervals, respectively, relative to the reference level (50th percentile). The dotted vertical lines correspond to the 10th, 25th, 50th, 75th, and 90 th percentiles of 15:0 concentrations. P-value for non-linearity=0.003 (CVD) and 0.009 (CHD).
Adjusted log hazard ratio for CVD risk
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